Epizyme Inc. (NASDAQ:EPZM)’s share price dropped 11.3% during trading on Monday . The company traded as low as $9.01 and last traded at $9.15, with a volume of 586,105 shares trading hands. The stock had previously closed at $10.32.

EPZM has been the subject of a number of analyst reports. JMP Securities restated a “buy” rating and issued a $28.00 price objective on shares of Epizyme in a research report on Thursday, June 23rd. Mizuho reaffirmed a “buy” rating and issued a $18.00 target price on shares of Epizyme in a research note on Monday, June 20th. Wedbush reaffirmed an “outperform” rating and issued a $22.00 target price on shares of Epizyme in a research note on Monday, May 9th. Leerink Swann reaffirmed a “buy” rating on shares of Epizyme in a research note on Tuesday, April 19th. Finally, Zacks Investment Research raised shares of Epizyme from a “sell” rating to a “hold” rating in a research note on Wednesday. One equities research analyst has rated the stock with a hold rating and nine have issued a buy rating to the stock. Epizyme currently has a consensus rating of “Buy” and a consensus price target of $23.11.

The company has a 50-day moving average of $10.01 and a 200-day moving average of $10.47. The firm’s market cap is $497.15 million.

Epizyme (NASDAQ:EPZM) last announced its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($0.49) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.52) by $0.03. On average, analysts predict that Epizyme Inc. will post ($2.24) EPS for the current fiscal year.

In related news, insider Robert A. Copeland sold 4,000 shares of the business’s stock in a transaction that occurred on Monday, August 1st. The stock was sold at an average price of $10.37, for a total transaction of $41,480.00. Following the completion of the transaction, the insider now directly owns 35,538 shares in the company, valued at approximately $368,529.06. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

A hedge fund recently bought a new stake in Epizyme stock. California Public Employees Retirement System acquired a new position in shares of Epizyme Inc. (NASDAQ:EPZM) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 170,000 shares of the biopharmaceutical company’s stock, valued at approximately $2,723,000. California Public Employees Retirement System owned about 0.41% of Epizyme at the end of the most recent quarter.

Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company’s segment is the discovery and development of novel epigenetic therapies for cancer patients. It develops small molecule inhibitors of a class of enzymes known as histone methyltransferases, or HMTs.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.